1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agree.
BridgeBio Pharma (BBIO) is the focus. Barclays analyst Eliana Merle reiterated an overweight rating and a $157 price target, citing Attruby, an FDA-approved heart drug. In Q1 2026, U.S. Attruby revenue was $180.6 million and total revenue $194.5 million. Barclays projects $912 million U.S. sales for 2026 versus $826 million consensus, with FDA decisions on BBP-418 (Nov 27, 2026) and Encaleret (May 8, 2027).
How this was made
The 30-second read
Why it matters
The trading relevance comes from the combination of (1) cited Q1 2026 Attruby revenue and patient/prescriber metrics, (2) a Barclays 2026 U.S. sales estimate above consensus, and (3) specific upcoming FDA decision dates for two pipeline assets.
Market read
This is a single-name bullish thesis piece that can influence BBIO positioning, but it does not introduce a new regulatory decision, earnings print, or deal.
What to watch
Execution risk remains high for a still-unprofitable biotech, and the piece does not provide new clinical or regulatory outcomes beyond existing approval and scheduled FDA review dates.
Background
BridgeBio’s Attruby was FDA-approved in late 2024 for transthyretin amyloid cardiomyopathy (ATTR-CM), and the article argues the commercial launch is exceeding expectations.
Ticker impact
BridgeBio Pharma is the article’s subject, with Barclays reiterating an overweight rating and a $157 price target tied to Attruby ramp and pipeline milestones.
Near-term price action is likely to track sentiment around the analyst target and the cited 2026 sales outlook, but follow-through depends on continued Attruby share gains and pipeline execution into late-2026/2027.
This is primarily an analyst-target and thesis article, not a new FDA decision or earnings print. However, it includes specific, time-relevant datapoints (Q1 2026 Attruby revenue, 2026 sales projection, and FDA decision dates) that can influence positioning and expectations.
Market effects
Reinforces positive sentiment toward ATTR-CM and broader cardiology/rare-disease commercial-stage biotech narratives, but it is not a sector-wide catalyst.
Limited, mostly impacts U.S. biotech sentiment and single-name positioning rather than macro/regional flows.
Low, as the drivers are company-specific FDA timelines and U.S. commercial performance.
Counterpoint
The article’s upside case is anchored to an analyst price target and sales ramp assumptions; if Attruby adoption slows or pricing/competition pressures emerge, the multiple expansion could reverse quickly.
Key entities
- companyBridgeBio Pharma
Subject of the article, with Barclays reiterating an overweight rating and $157 price target based on Attruby ramp and pipeline catalysts.
- productAttruby
Commercial heart drug whose U.S. sales momentum is used to support the bullish thesis.
- pipeline_programBBP-418
FDA review for limb-girdle muscular dystrophy, with a decision expected by Nov. 27, 2026.
- pipeline_programEncaleret
FDA review for autosomal dominant hypocalcemia type 1, with a decision scheduled by May 8, 2027.
